Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-07-12
2005-07-12
Tate, Christopher R. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S327000, C530S328000, C530S329000, C530S330000, C514S017400
Reexamination Certificate
active
06916903
ABSTRACT:
Peptides synthesized to match C-telopeptide components of type III collagen degradation products in body fluids, selected from among EKAGGF (SEQ ID NO:39), IGGEKAGG (SEQ ID NO:40), IGGEKAGGF (SEQ ID NO:41), IAGIGGEKAGG (SEQ ID NO:42), IAGIGGEKAGGF (SEQ ID NO:43), and EKAGG (SEQ ID NO:44) are useful as immunogens and antigens in collagen resorption assays.
REFERENCES:
patent: 4312853 (1982-01-01), Timpl
patent: 4504587 (1985-03-01), Timpl et al.
patent: 4628027 (1986-12-01), Gay
patent: 4973666 (1990-11-01), Eyre
patent: 5140103 (1992-08-01), Eyre
patent: 5300434 (1994-04-01), Eyre
patent: 5316914 (1994-05-01), Oshima et al.
patent: 5320970 (1994-06-01), Eyre
patent: 5342756 (1994-08-01), Risteli et al.
patent: 5702909 (1997-12-01), Eyre
patent: 5817755 (1998-10-01), Eyre et al.
patent: 1287801 (1991-08-01), None
patent: 0 089 008 (1983-09-01), None
patent: 0 289 930 (1988-11-01), None
patent: 0 298 210 (1989-01-01), None
patent: 0 304 292 (1989-02-01), None
patent: 0 339 443 (1989-11-01), None
patent: 0 505 210 (1992-09-01), None
patent: 0 699 752 (1996-03-01), None
patent: 0 718 309 (1996-06-01), None
patent: 2 205 643 (1988-12-01), None
patent: WO 88/08980 (1988-11-01), None
patent: WO 89/04491 (1989-05-01), None
patent: WO 89/12824 (1989-12-01), None
patent: WO 91/08478 (1991-06-01), None
patent: WO 91/08478 (1991-06-01), None
patent: WO 92/21698 (1992-12-01), None
patent: WO 94/03813 (1994-02-01), None
patent: WO 94/14070 (1994-06-01), None
patent: WO 94/14844 (1994-07-01), None
patent: WO 94/18563 (1994-08-01), None
patent: WO 95/04282 (1995-02-01), None
patent: WO 95/08115 (1995-03-01), None
patent: WO 96/12193 (1996-04-01), None
patent: WO 96/36645 (1996-11-01), None
Ala-Kokko, L., et al., “Structure of cDNA Clones Coding for the Entire Preproα1(III) Chain of Human Type III Precollagen,”Biochem. J.260:509-516, 1989.
Seibel, M.J., “Komponenten der extrazellulären Gewebematrix als potentielle-Marker” des Bindegewebs-, Knorpel- und Knochenmetabolismus bei Erkrankungen des Bewegungsapparates,Z. Rheumatol.48:6-18, 1989.
Niemelä, O., “Radioimmunoassays for Type III Procollagen Amino-Terminal Peptides in Humans,”Clin. Chem.31(8):1301-1304, 1985.
Loid, H.R., et al., “Molecular Cloning and Carboxyl-Propeptide Analysis of Human Type III Procollagen,”Nucleic Acids Research12(24):9383-9394, 1984.
Pierard, D., et al., “Radioimmunoassay for the Amino-Terminal Sequences of Type III Procollagen in Human Body Fluids Measuring Fragmented Precursor Sequences,”Analytical Biochem.141:127-136, 1984.
Rohde, H., et al., “Radioimmunoassay for Type III Procollagen Peptide and Its Application to Human Liver Disease,”Euro. J. Clin. Invest.9:451-459, 1979.
Eyre, D.R., “Cross-Linking in Collagen and Elastin,”Ann. Rev. Biochem.53:717-748, 1984.
Hasselbalch, H., et al., “Procollagen Type III Aminoterminal Peptide in Serum in Idiopathic Myelofibrosis and Allied Conditions: Relation to Disease Activity and Effect of Chemotherapy,”Am. J. Hematol.33:18-26, 1990.
Hanson, D.A., et al., “A Specific Immunoassay for Monitoring Human Bone Resorption: Quantitation of Type I Collagen Cross-Linked N-Telopeptides in Urine,”J. Bone and Min. Res.7(11):1251-1258, 1992.
Lane, J.M., et al., “Immunofluorescent Localization of Structural Collagen Types in Endochondral Fracture Healing,”Orthopaedic Transactions VI(2):236, 1982.
Kühn, K., “The Classical Collagens: Types I, II, and III,” inStructure and Function of Collagen Types, Academic Press, Inc., 1987, pp. 1-42.
Stoltenberg, M., et al., “Intra-Articular and Circulating Levels of Type and I and III Collagen Markers in Inflammatory and Degenerative Joint Disease,”Acta. Orthop. Scand.66(Suppl 266):147-148, 1995.
Eyre, D.R., et al., “Cross-Linked Telopeptides From Collagen Types I, II and III in Human Urine,” ASBMR Meeting, Sep. 1996.
Horslev-Petersen, K., “Circulating Extracellular Matrix Components as Markers for Connective Tissue Response to Inflammation,”Danish Med. Bul.37(4):308-329, 1990.
Hanson, D.A., and D.R. Eyre, “Molecular Site Specificity of Pyridinoline and Pyrrole Cross-Links in Type I Collagen of Human Bone,”J. Biol. Chem.271(43):26508-26516, 1996.
Myllylä, R., et al., “Markers of Collagen Metabolism in Sera of Patients With Various Rheumatic Disease,”Clinica Chimica Acta183:243-252, 1989.
Macarak, E.J., et al., “Production and Characterization of a Monoclonal Antibody to Human Type III Collagen,”J. Histochem. Cytochem.34(8):1003-1011, 1986, inChem. Abstracts105:95762y, 1986.
Macarak, E.J., et al., “Production and Characterization of a Monoclonal Antibody to Human Type III Collagen,”J. Histochem. and Cytochem.34(8):1003-1011, 1986.
Otter, A., et al., “Conformational Analysis of the Type II and III Collagen α-1 Chain N-Telopeptides by Proton-NMR Spectroscopy and Restrained Molecular Mechanics Calculations,”Biopolymers33(9):1443-1459, 1993, inChem. Abstracts119:264860a, 1993.
Gosslau, B., and H.-J. Barrach, “Enzyme-Linked Immunosorbent Microassay for Quantification of Specific Antibodies to Collagen Type I, II, III,”J. Immunol. Meth.29:71-77, 1979.
Atley, L., et al., “A Selective Inhibitor of Collangenase-3 Blocks the Release of Hydroxyproline and a Metalloproteinase Specific Neoepitope, Coll II CTx, From Bovine Cartilege Exposed to IL-1α,”Arth. Rheum.40(9S):584, 1997.
Niemelä, O., et al., “Heterogeneity of the Antigens Related to the Aminoterminal Propeptide of Type III Procollagen in Human Serum,”Clinica Chimica Acta124:39-44, 1982.
Atley, L.M., et al., “Matrix Metalloproteinase-Mediated Release of Immunoreactive Telopeptides From Cartilage Type II Collagen,”44th Annual Meeting, Orthop. Res. Soc., New Orleans, Mar. 16-19, 1998.
Moskowitz, R.W., et al., “Type II Collagen C-Telopeptide 2B4 Epitope Is a Marker for Cartilage Degradation in Familial Osteoarthritis,”Meeting of Amer. Coll. Rheum., San Diego, Nov. 8-12, 1998.
Eyre, D.R., et al., “Biochemical Markers of Bone and Cartilage Collagen Degradation,”Combined Orthopaedic Research Societies Meeting, Vittel, France, Sep. 28-30, 1998.
Sheridan, C., “Osteometer Targets Collagen for Osteoporosis, Arthritis Tests,”BioWorld International, Dec. 3, 1997, p. 3.
Atley, L.M., et al., “Collagen Type II Cross-Linked Telopeptides, a Promising Marker for Cartilage Degradation in Arthritis,”Combined Orthopaedic Research Societies Meeting, Hamamatsu, Japan, 1998.
Otter, A., et al., “Conformational Analysis of the Type II and Type III Colagen α-1 Chain N-Telopeptides by H-NMR Stpectroscopy and Restrained Molecular Mechanics Calculations,”Biopolymers33:1443-1459, 1993.
Christensen O'Connor Johnson & Kindness PLLC
Harle Jennifer Ione
Tate Christopher R.
Washington Research Foundation
LandOfFree
Collagen type III synthetic peptides for collagen resorption... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Collagen type III synthetic peptides for collagen resorption..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Collagen type III synthetic peptides for collagen resorption... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398881